 |
|
|
|
 |
egories |
 |
 |
New Addition |
 |
|
|
 |
Details: |
 |
|
|
Oncology studies in small molecule histone deacetylase and topoisomerase II inhibitors, with clinical trials in solid tumours, CNS and extravasation. Technology and profile of company with facilities in Copenhagen and Abingdon, England.
|
| URL: |
|
| Title: |
|
| Description: |
Business, Biotechnology and Pharmaceuticals, Cancer Research - Topotarget. Oncology studies in small molecule histone deacetylase and topoisomerase II inhibitors, with clinical trials in solid tumours, CNS and extravasation. |
| Specialized in: |
|
|
 |
|
 |
PNP Therapeutics, Inc. (Popularity: ): Company developing gene therapy system, using the E. coli enzyme, purine nucleoside phosphorylase, to induce suicide in tumor cells. Includes ...
Onyvax Ltd. (Popularity: ): Conducts research and development for marketing cell-based vaccines and human monoclonal antibody against CD55 in tumour cells. Includes explanation of ...
Aventis Cancer Vaccine Program (Popularity: ): Studying the possibilities of using an immunotherapeutic approach for melanoma, breast and colorectal and tumors. Includes results of clinical research, ...
Biomoda, Inc. (Popularity: ): Offers products for diagnosis, imaging and treatment of tumors, especially in lung. Technologies in sputum sample and pap smear screening, ...
Crusade Laboratories Ltd. (Popularity: ): Start-up focusing on the discovery, development and commercialisation of novel treatments for tumors and neurodegenerative diseases. Includes investor information, technology ...
Cancer Survival Toolbox (Popularity: ): Introduction the mechanisms, with resources in oncology, vascular medicine and immunolgical disease, including possible therapies and links to related organizations, ...
Bath Cancer Research (Popularity: ): Offers cytotoxicity screening for potential drugs, and ex vivo drug sensitivity cell testing, for non-Hodgkin's lymphoma, chronic and acute leukaemias, ...
InterGenetics Inc. (Popularity: ): Company with platform technology, called CombiSNiP, that genetically quantifies an individual's risk for development, and is involved in pharmacogenetics research ...
GeneSegue (Popularity: ): Focusing on the development of delivery systems to target solid tumors, such as prostate with nanoencapsulated biotherapeutics. Includes brief overview ...
Karyon (Popularity: ): Offers products in angiogenesis and cell growth regulation, focusing on protected ligands that target specifically to sarcomas and melanomas. Includes ...
|
 |
Popular Sites |
 |
Biomoda, Inc. (Popularity: ): Offers products for diagnosis, imaging and treatment of tumors, especially in lung. Technologies in sputum sample and pap smear screening, ...
InterGenetics Inc. (Popularity: ): Company with platform technology, called CombiSNiP, that genetically quantifies an individual's risk for development, and is involved in pharmacogenetics research ...
Aventis Cancer Vaccine Program (Popularity: ): Studying the possibilities of using an immunotherapeutic approach for melanoma, breast and colorectal and tumors. Includes results of clinical research, ...
AC Immune SA. (Popularity: ): Focus on CNS conformational diseases and oncology, using a combination of antibodies produced to non-covalent complexes of peptide sequences, presented ...
PNP Therapeutics, Inc. (Popularity: ): Company developing gene therapy system, using the E. coli enzyme, purine nucleoside phosphorylase, to induce suicide in tumor cells. Includes ...
|
 |
Related Press |
 |
Tiny Tweezers and Yeast Help St. Jude Show How Cancer Drug Works (Popularity: ): The annoying bulges of an over-wound telephone cord that shorten its reach help to explain why drugs called camptothecins are ...
GlaxoSmithKline and Cellzome Announce Major Strategic Alliance (Popularity: ): Cellzome Inc. and GlaxoSmithKline (LSE & NYSE: GSK) announce the signing of a worldwide strategic alliance to discover, develop and ...
MEDRAD Introduces New Extravasation Detector Technology (Popularity: ): MEDRAD, INC. introduced a new extravasation detector technology for the Stellant(R) CT Injection System that, for the first time, directly ...
Pharmacyclics Announces Encouraging Phase 2 Data With Xcytrin(R) in Recurrent Non-Small Cell Lung Cancer Patients (Popularity: ): Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from three open-label, multi-center Phase 2 clinical trials evaluating Xcytrin(R) (motexafin gadolinium) Injection, ...
Quest Group International, Inc. Raises $20 Million, Acquires Extensive New Generation Oncology Portfolio and Announces Three Lead Therapeutic Product Programs (Popularity: ): Quest Group International, Inc. ("Quest") (OTC Bulletin Board: QSTG) today announced that it entered into a license agreement with Vitae ...
|
 |
Related Articles |
 |
|
|
 |
|
 |
| |
| | |
|
|
|
© 2003-2008, ABC-Directory.Com. All Rights Reserved
|
|
|
 |
|
 |
|